Thyroxine Increases Collagen Type II Expression and Accumulation in Scaffold-Free Tissue-Engineered Articular Cartilage

• Published in: Tissue engineering. Part A Vol. 24; no. 5-6; pp. 369 - 381
• Main Authors: Whitney, G. Adam, Kean, Thomas J., Fernandes, Russell J., Waldman, Stephen, Tse, M. Yat, Pang, Stephen C., Mansour, Joseph M., Dennis, James E.
• Format: Journal Article
• Language: English
• Published: United States Mary Ann Liebert, Inc 01.03.2018
• Subjects: Animals; Biology; Biomedical engineering; Bone surgery; Cartilage (articular); Cartilage, Articular - cytology; Cartilage, Articular - metabolism; Chondrocytes; Chondrocytes - cytology; Chondrocytes - metabolism; Chondrogenesis; Collagen; Collagen (type I); Collagen (type II); Collagen Type II - biosynthesis; Deoxyribonucleic acid; DNA; Dose-Response Relationship, Drug; Drug dosages; Engineering; Extracellular matrix; Gene expression; Gene Expression Regulation - drug effects; Hormones; Kinases; Male; Mechanical properties; Original; Original Articles; Orthopedics; Protein folding; Proteins; Rabbits; Statistical analysis; Studies; Thyroid gland; Thyroid hormones; Thyroxine; Thyroxine - pharmacology; Tissue Engineering; Transforming growth factor-b1; Western blotting; Canada; Cleveland Ohio; Ohio; United States > US; Texas; thyroxine; engineered cartilage; extracellular matrix composition; chondrogenesis; collagen-to-GAG ratio; collagen type II
• DOI: 10.1089/ten.tea.2016.0533
• ISSN: 1937-3341

Low collagen accumulation in the extracellular matrix is a pressing problem in cartilage tissue engineering, leading to a low collagen-to-glycosaminoglycan (GAG) ratio and poor mechanical properties in neocartilage. Soluble factors have been shown to increase collagen content, but may result in a more pronounced increase in GAG content. Thyroid hormones have been reported to stimulate collagen and GAG production, but reported outcomes, including which specific collagen types are affected, are variable throughout the literature. Here we investigated the ability of thyroxine (T4) to preferentially stimulate collagen production, as compared with GAG, in articular chondrocyte-derived scaffold-free engineered cartilage. Dose response curves for T4 in pellet cultures showed that 25 ng/mL T4 increased the total collagen content without increasing the GAG content, resulting in a statistically significant increase in the collagen-to-GAG ratio, a fold change of 2.3 ± 1.2, p  < 0.05. In contrast, another growth factor, TGFβ1, increased the GAG content in excess of threefold more than the increase in collagen. In large scaffold-free neocartilage, T4 also increased the total collagen/DNA at 1 month and at 2 months (fold increases of 2.1 ± 0.8, p  < 0.01 and 2.1 ± 0.4, p  < 0.001, respectively). Increases in GAG content were not statistically significant. The effect on collagen was largely specific to collagen type II, which showed a 2.8 ± 1.6-fold increase of COL2A1 mRNA expression ( p  < 0.01). Western blots confirmed a statistically significant increase in type II collagen protein at 1 month (fold increase of 2.2 ± 1.8); at 2 months, the fold increase of 3.7 ± 3.3 approached significance ( p  = 0.059). Collagen type X protein was less than the 0.1 μg limit of detection. T4 did not affect COL10A1 and COL1A2 gene expression in a statistically significant manner. Biglycan mRNA expression increased 2.6 ± 1.6-fold, p  < 0.05. Results of this study show that an optimized dosage of T4 is able to increase collagen type II content, and do so preferential to GAG. Moreover, the upregulation of COL2A1 gene expression and type II collagen protein accumulation, without a concomitant increase in collagens type I or type X, signifies a direct enhancement of chondrogenesis of hyaline articular cartilage without the induction of terminal differentiation.